Covalon announces introduction of new MediClear product line to reduce surgical site infections

Covalon Technologies Ltd, (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the introduction of its new MediClear™ product line designed to significantly improve patient compliance with efforts to reduce surgical site infections (SSI).

Included in the MediClear™ line is Covalon's patent-pending MediClear™ PreOp – Antimicrobial Silicone Film Dressing, designed to replace other pre-operative skin preparation products, Covalon's next generation antimicrobial MediClear™ PostOp dressing and MediClear™ Scar. All three will be presented at AORN (Association of Perioperative Registered Nurses) Surgical Conference & Expo.

"MediClear™ PreOp, PostOp and Scar will meet the growing demand for infection management and post-operative scar reduction products, and are the latest examples of Covalon's innovation in antimicrobial silicone adhesive technologies" said John R. Hands, Senior Director of Marketing at Covalon.

Preoperative skin preparation products are a critical part of an infection control bundle, aimed at reducing surgical site infections (SSIs). A 2014 study suggested SSIs account for in excess of $3.5 billion in healthcare expenditures per year in the United States, not including the additional costs of hospitalization, post-discharge outpatient expenses, and long-term disability care and management. Covalon's MediClear™ line is intended to help reduce this financial burden on the U.S. healthcare system.

MediClear™ PreOp – Silicone Film Dressing for PreOperative Skin Preparation with Chlorhexidine and Silver provides perioperative professionals with a patent-pending solution to patient non-compliance that exists with current chlorhexidine soap and wipe modalities.

"A product only works if a patient uses it, and we know that complicated instructions are a factor in patient non-compliance for traditional skin preparations" said Hands. "MediClear PreOp's application and comfort removes compliance as an issue, while also delivering continuous bactericidal and re-growth suppression for up to 7 days before the patient's surgery."